Pegaptanib
- Generic Name
- Pegaptanib
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 222716-86-1
- Unique Ingredient Identifier
- 3HP012Q0FH
- Background
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.
- Indication
For the treatment of neovascular (wet) age-related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1001
- Registration Number
- NCT01245387
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT01189461
- Locations
- 🇪🇸
Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
🇸🇪Ogonkliniken, Centrallasarettet, Vasteras, Sweden
🇬🇧Kings College Hospital, London, United Kingdom
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 243
- Registration Number
- NCT01100307
- Locations
- 🇯🇵
Kohnan Hospital, Kobe, Hyogo, Japan
🇯🇵Nihon University Surugadai Hospital, Chiyoda-ku, Tokyo, Japan
🇯🇵Shiga University of Medical Science Hospital, Otsu, Shiga, Japan
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00858208
- Locations
- 🇬🇷
Pfizer Investigational Site, Xanthi, Greece
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3538
- Registration Number
- NCT00845273
Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 5
- Registration Number
- NCT00790803
- Locations
- 🇺🇸
Wake Forest University Eye Center, Winston-Salem, North Carolina, United States
The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2008-05-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 1
- Registration Number
- NCT00358423
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-05-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 4
- Registration Number
- NCT00346983
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
- Conditions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2006-05-04
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00321997
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
- Conditions
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 262
- Registration Number
- NCT00312351
- Locations
- 🇺🇸
Charlotte Eye, Ear, Nose and Throat Associates, P.A., Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.